Reshma Kewalramani, one of the Council’s 2021 New Englander of the Year honorees, and the chief executive of Vertex Pharmaceuticals, will be joining the board of Ginkgo Biowork. Ginkgo Bioworks, a Boston based startup, is planning to go public after merging with Soaring Eagle Acquisition Corp.
In a press release, Kewalramani said, “I am excited to join Ginkgo’s board of directors at such a pivotal time. . . I am particularly excited by the company’s broad platform, which holds the potential to meaningfully transform multiple fields from agriculture to energy to life sciences.”
Kewalramani has served as the CEO of Vertex since April 2020, after previously serving as Chief Medical Officer at the Cambridge, MA-headquartered global pharmaceutical company. She also serves on the boards of the Biomedical Science Careers Program, an organization dedicated to supporting underrepresented students to pursue a career in STEM, and RIZE Massachusetts, a nonprofit foundation focused on ending the opioid epidemic.
The NEC congratulates Dr. Kewalramanion this new role, and looks forward to celebrating her achievements during our Annual Celebration on October 18. Read more about it in the Boston Globe.
Recently from the Blog
NEC Announces COVID In-Person Event Policy; Plans Return to In-Person Programming in 2022
